DoW Alzheimer’s Transforming Research Award
About
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD). Distinctive Features: • Applications must address at least one of the following focus areas: ○ Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. ○ Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD. • Clinical research is allowed, however clinical trials and animal research are prohibited. • Preliminary data are required. • Community collaboration is required for research prospectively enrolling human subjects. • Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet.
The DoW Alzheimer's Transforming Research Award supports researchers and scientific teams pursuing non-incremental, transformative research that advances our understanding and prevention of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FY2026 program is ideal for investigators who are developing innovative solutions in risk factor identification, validation, and reduction strategies. The award funds research addressing environmental, epigenetic, genetic, lifestyle, occupational, and other risk factors, as well as methods and technologies that contribute to preventing AD/ADRD. Researchers can conduct clinical research, but clinical trials and animal studies are not permitted. The program requires preliminary data and mandates community collaboration for projects involving human subjects. A distinctive Career Initiation or Transition (CIT) Partnership Option allows multiple independent investigators to collaborate, with each PI receiving a separate award to their respective organizations. This grant is designed for established researchers and emerging scientists ready to make meaningful contributions to Alzheimer's disease prevention and risk reduction through rigorous, well-designed research that stands to transform the field.
Funding Facts
● Applications openDeadline
September 24, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount not specified; varies by cycle
Deadline
2026-09-24
Grant Type
federal
Application Cycle
Annual (FY2026 deadline: September 24, 2026)
Best For
Academic researchers, research institutions, and independent investigators focused on Alzheimer's disease prevention and risk reduction
Frequently Asked Questions
Who is eligible for DoW Alzheimer's Transforming Research Award?
Specific eligibility criteria were not provided in the available information. However, based on the program description, eligible applicants likely include academic researchers, research institutions, and independent investigators with the capacity to conduct rigorous research on Alzheimer's disease prevention and risk reduction. The program supports both established researchers and those utilizing the Career Initiation or Transition (CIT) Partnership Option. For complete and current eligibility requirements, visit the official Department of War (DoW) or administering agency website.
How much funding does DoW Alzheimer's Transforming Research Award provide?
The specific funding amount or range for this award cycle was not provided in the available information. Award amounts may vary by fiscal year and research scope. Contact the administering agency directly or consult the official program announcement for current funding levels and budget guidelines.
How do I apply for DoW Alzheimer's Transforming Research Award?
Applications for the FY2026 cycle have a deadline of September 24, 2026. Applicants should prepare proposals addressing at least one focus area: Risk Factor Knowledge or Risk Reduction Solutions. All applications must include preliminary data and, for human subject research, evidence of community collaboration. For detailed submission instructions, required forms, and the official application portal, visit the Department of War or the designated funding agency's website.
What can DoW Alzheimer's Transforming Research Award funding be used for?
Funding supports transformative research that advances understanding, identification, and validation of risk and protective factors for Alzheimer's disease and related dementias. Research can focus on developing methods, technologies, and strategies for risk reduction and disease prevention. Clinical research is permitted, though clinical trials and animal research are prohibited. Allowable projects include studies on environmental, epigenetic, genetic, lifestyle, and occupational risk factors. The award also supports collaborative research through the Career Initiation or Transition Partnership Option, enabling multiple independent investigators to work together.
Last updated: July 5, 2026